Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 6/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.43 |
| ▸ | MAPT | P10636 | 4/20 | 0.43 |
| ▸ | HPGD | P15428 | 4/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.40 |
| ▸ | GP6 | Q9HCN6 | 1/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.37 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.37 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.37 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20080925 | 1.00 | MEN1 (0.43) | MEN1KMT2AMAPTHPGDALDH1A1 | |
| SCHEMBL20080924 | 0.98 | MEN1 (0.42) | MEN1KMT2AMAPTHPGDALDH1A1 | |
| SCHEMBL20080976 | 0.98 | MEN1 (0.42) | MEN1KMT2AMAPTHPGDALDH1A1 | |
| SCHEMBL18180827 | 0.98 | MEN1 (0.42) | MEN1KMT2AMAPTHPGDALDH1A1 | |
| SCHEMBL26023213 | 0.97 | MEN1 (0.43) | MEN1KMT2AMAPTHPGDALDH1A1 | |
| SCHEMBL24098353 | 0.97 | MEN1 (0.43) | MEN1KMT2AMAPTHPGDALDH1A1 | |
| SCHEMBL22722731 | 0.97 | MEN1 (0.43) | MEN1KMT2AMAPTHPGDALDH1A1 | |
| SCHEMBL19497364 | 0.97 | L3MBTL1 (0.41) | MEN1KMT2AMAPTHPGDALDH1A1 | |
| SCHEMBL22722729 | 0.97 | MEN1 (0.43) | MEN1KMT2AMAPTHPGDALDH1A1 | |
| SCHEMBL20080954 | 0.97 | L3MBTL1 (0.41) | MEN1KMT2AMAPTHPGDALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11530201-B2 | Triazine compounds substituted with bulky groups | NOVALED GMBH (DE) | 2022-12-20 | — | — | US | disclosed |
| US-10851056-B2 | Compound for organic optoelectronic device, organic optoelectronic device and display apparatus | SAMSUNG SDI CO., LTD. (KR) | 2020-12-01 | — | — | US | disclosed |
| US-20200361916-A1 | Triazine Compounds substituted with Bulky Groups | SAMSUNG SDI CO. LTD. (KR) | 2020-11-19 | — | — | US | disclosed |
| EP-3502106-B1 | TRIAZINE COMPOUNDS SUBSTITUTED WITH BULKY GROUPS | NOVALED GMBH (DE) | 2020-09-02 | — | — | EP | disclosed |
| EP-3502106-A1 | TRIAZINE COMPOUNDS SUBSTITUTED WITH BULKY GROUPS | Novaled GmbH (DE) | 2019-06-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10851056-B2 | Compound for organic optoelectronic device, organic optoelectronic device and display apparatus | OXER1, OR10J3, AOX1 | MEN1 2402/4885KMT2A 3536/4885MAPT 2972/4885 |
| US-11530201-B2 | Triazine compounds substituted with bulky groups | POU5F1, POU2F1, IKZF2 | MEN1 1203/4885KMT2A 465/4885MAPT 3013/4885 |
| US-20200361916-A1 | Triazine Compounds substituted with Bulky Groups | POU5F1, POU2F1, IKZF2 | MEN1 1203/4885KMT2A 465/4885MAPT 3013/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.